The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug

Ferro, V. and Don, R. (2003) The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug. Australasian Biotechnology, 13 1: 38-39.


Author Ferro, V.
Don, R.
Title The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug
Journal name Australasian Biotechnology   Check publisher's open access policy
ISSN 1036-7128
Publication date 2003-02
Sub-type Article (original research)
Volume 13
Issue 1
Start page 38
End page 39
Total pages 2
Place of publication Malvern, Vic., Australia
Publisher AusBiotech
Language eng
Subject 1112 Oncology and Carcinogenesis
Abstract The novel sulfated oligosaccharide agent PI-88 is being developed by the Australian biotechnology company, Progen Industries Limited, as an anticancer drug. PI-88 is an inhibitor of angiogenesis, that is, the growth of new blood vessels from pre-existing ones surrounding a tumour. PI-88 also blocks the spread of tumour cells (metastasis) by inhibition of the key enzyme heparanase. PI-88 is currently in Phase II trials as a monotherapy and in Phase I as a combination therapy with the cytotoxic drug Docetaxel.
Keyword Angiogenesis inhibitor PI-88
Anti-cancer drugs
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Chemistry and Molecular Biosciences
 
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 30 Mar 2010, 14:49:27 EST by June Temby on behalf of Faculty of Science